Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026)

Enliven Therapeutics has disclosed Return on Capital Employed across 7 years of filings, most recently posting 3.9% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 3.9%, up 3283.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3.9% (up 3283.0% YoY), and the FY2025 annual result was 5.66%, up 3129.0% from the prior year.
• Return on Capital Employed came in at 3.9% for Q1 2026 at Enliven Therapeutics, up from 4.66% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 3.9% in Q1 2026 to a low of 71.52% in Q3 2022.
• The 5-year median for Return on Capital Employed is 32.98% (2024), against an average of 35.2%.
• Across the five-year window, Return on Capital Employed slumped 1259 bps in 2022 and soared 4530 bps in 2023, its largest moves.
• Enliven Therapeutics' Return on Capital Employed stood at 63.09% in 2022, then soared by 46 bps to 33.81% in 2023, then slipped by 3 bps to 34.89% in 2024, then surged by 87 bps to 4.66% in 2025, then rose by 16 bps to 3.9% in 2026.
• The last three Return on Capital Employed figures came in at 3.9% (Q1 2026), 4.66% (Q4 2025), and 23.26% (Q3 2025), per Business Quant data.